Scribe Therapeutics Director Buys 4,755 Shares, Signals Strong Confidence in LDL‑C Gene‑Editing Breakthrough.
Insider buys Scribe Therapeutics shares, signaling confidence in its CRISPR‑LDL‑C therapy and strong partnership with Sanofi.
2 minutes to read